drugset / Trial / NCT00856206

Review of Safety Using Rilonacept in Preventing Gout Exacerbations (RE-SURGE)

NCT00856206

Phase 3 Completed 1315 enrolled Regeneron Pharmaceuticals
RandomizedParallel-groupQuadruple-blindPrevention

Summary

The purpose of this clinical research study is to determine the safety and effectiveness of an experimental drug called rilonacept in subjects with gout who are on urate-lowering therapy. Subjects will participate in this study for approximately 20 weeks. Rilonacept is being studied for use in preventing gout flares in subjects on urate-lowering therapy.

Timeline

Start
2009-03
Primary completion
2011-01
Completion
2011-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Rilonacept Protein / enzyme biologic 160 mg Subcutaneous

Indications